Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy

\<Polypoidal choroidal vasculopathy group\> Inclusion Criteria: * Male or Female patients ≥ 45yrs of age * Best corrected Visual acuity 20/30 to 20/320 Snellen equivalent using ETDRS chart measured at 4 meters * Signed written informed consent * Evidence of Polypoidal choroidal vasculopathy , active in disease activity. * Presence of subfoveal, juxtafoveal or extrafoveal active characteristic macular polypoidal lesions on indocyanine green angiography * Confirmed to be active in disease activity by fluorescein angiography * The total lesion must have the greatest linear dimension less than 5400 microns ( \~9 MPS Disc Areas ) as delineated by indocyanine green angiography * Had not been treated in the past * Patients willing and able to comply with all study procedures Exclusion Criteria: * Previous history of laser photocoagulation,photodynamic therapy,anti VEGF therapy, submacular surgery in the study eye * Have known hypersensitivity to Visudyne® and Lucentis™ * Previous treatment with external-beam radiation therapy or transpupillary thermotherapy * History of vitrectomy * Intraocular surgery,yttrium aluminum garnet(YAG) laser\< 1month before day 0 * Additional eye disease that could compromise visual acuity * Ocular inflammation * Vitreous hemorrhage * Uncontrolled glaucoma * Current use or of likely need for systemic medications known to be toxic to the eye. * Inability to obtain fluorescein angiography and indocyanine green angiography, due to media opacity, allergy to the dye or lack of venous access * Are participating in another clinical study. * Disciform scar * Mental illness that precludes the patient from giving informed consent * Patients who are considered potentially unreliable \<Control group\> -Age matched patients with cataract without other ocular diseases such as glaucoma, high myopia, ocular ischemic diseases, retinal disease, or with systemic diseases like diabetes mellitus.